Annual report pursuant to Section 13 and 15(d)

Nature of Business (Details Narrative)

v3.8.0.1
Nature of Business (Details Narrative) - USD ($)
Nov. 21, 2017
Oct. 04, 2017
Oct. 02, 2017
Dec. 31, 2017
Dec. 31, 2016
Common stock issued       35,272,626 31,745,242
Common stock shares outstanding       35,272,626 31,745,242
Captial stock shares authorized       350,000,000 43,261,049
Common stock par value       $ 0.0001 $ 0.0001
Preferred stock shares authorized       10,000,000 10,000,000
Preferred stock par value       $ 0.0001 $ 0.0001
Accumulated deficit       $ 3,859,086 $ 2,002,771
Funding of drugs   $ 8,000,000      
First Tranche [Member]          
Senior convertible notes convert into securities   $ 1,250,000      
Senior convertible notes offering percentage   greater than 90%      
Additional Tranche [Member] | Investors [Member]          
Senior convertible notes convert into securities $ 1,330,000        
Parent Company [Member]          
Number of shares acquired in exchange for common stock     222,217,112    
Precentage of issued and outstanding common stock diluted basis     90.00%    
Common stock issued       246,907,902  
Common stock shares outstanding       246,907,902  
Number of shares owned by shareholders     246,907,902    
Captial stock shares authorized     350,000,000    
Common stock par value     $ 0.0001    
Preferred stock shares authorized     10,000,000    
Preferred stock par value     $ 0.0001    
Parent Company [Member] | Series D Preferred Stock [Member]          
Common stock issued     13,673,402